TMO
Thermo Fisher Scientific Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$608.30
−1.64%Year over year
Reported trailing growth
- Revenue
- +7.2%
- EBITDA
- -4.1%
- EBIT
- +3.2%
- EPS
- +7.4%
- Free cash flow
- +18.6%
- Operating cash flow
- +18.9%
Forward estimates
Based on analyst estimates
- Revenue
- +5.8%
- EBITDA
- +28.9%
- EPS
- +40.9%
Three-year CAGR
- Revenue
- -0.3%
- EBITDA
- -1.3%
- EBIT
- -1.7%
- Net income
- -1.0%
- EPS
- +0.1%
- Free cash flow
- -3.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026